Report Events

[Registration Open] (Webinar) The 110th HGPI Seminar – Deepening Industry-Academia Collaboration on iNPH Measures and Steps for Real-World Implementation (December 16, 2022)

[Registration Open] (Webinar) The 110th HGPI Seminar – Deepening Industry-Academia Collaboration on iNPH Measures and Steps for Real-World Implementation (December 16, 2022)

Health and Global Policy Institute (HGPI) is being undertaken an initiative titled, “Current Issues and Future Prospects for Idiopathic Normal Pressure Hydrocephalus (iNPH) Measures – Focusing on a Form of Dementia that Improves with Treatment.” FY2022.

Projections show that the number of people living with dementia in Japan will soon exceed 7 million, and hopes are high for treatments that relieve the symptoms of dementia and address its underlying causes for better living later in life. Many diseases that cause dementia are considered difficult to treat, but iNPH is a form of dementia that improves with treatment. It is estimated that iNPH affects around 370,000 people, or about 5% of all people living with dementia. Furthermore, as pointed out in recent years, iNPH often occurs alongside Alzheimer’s disease, the most common cause of dementia, so the actual number of cases likely exceeds estimates. There are many potential benefits to delivering the appropriate treatments to people with iNPH. In addition to longer life expectancies, these include fall prevention and high returns in terms of health economics. As demonstrated by developments like the adoption of the “Research Survey on Structuring Healthcare for a Treatable Form of Dementia” as a Ministry of Health, Labour and Welfare Project for the Promotion of Well-Being for Elderly People, it is also gradually becoming a more important policy topic.

However, there are scattered issues that must be addressed before iNPH treatments can be delivered to as many people as possible to improve their symptoms and elevate their quality of life. First, despite the importance of early and accurate diagnosis, compared to the various other forms of dementia, it is difficult to say that awareness toward iNPH is high among civil society, healthcare providers, and long-term care providers. Second, iNPH can manifest as a broad variety of symptoms, and this requires collaboration across disciplines to address. After specialists from various fields examine a person to diagnose them with iNPH, they must work together with neurosurgeons who perform shunt procedures. Furthermore, to expand and enhance systems providing these treatments, there are various regional disparities that must be alleviated, so expectations are high for steps to achieve nationwide care equity.

If utilized effectively, technology can pose a solution to these issues. For example, video-based gait analyses can help physicians detect gait disturbance, one of the three signs of iNPH (which are gait disturbance, dementia, and urinary symptoms). Gait disturbance is recognized as a common early sign of iNPH and is said to improve the most with treatment. Technology can make diagnosis possible even when the attending physician is not a specialist, which may increase the likelihood that diagnosis and treatment will be provided at early stages.

For our upcoming seminar, we will host Dr. Shigeki Yamada of Nagoya City University Graduate School. He will discuss the current situation surrounding iNPH, clinical studies involving industry-academia collaboration to examine automatic image recognition technology based on AI or the automated detection of gait disturbance, and issues and future prospects for implementing the use of such technology in society.

Please note that this seminar is available in Japanese only. An English report of this event will be published in due course.


Dr. Shigeki Yamada (Lecturer, Department of Neurosurgery, Graduate School of Medical Sciences, Nagoya City University)

■Date & time:
Friday, December, 16, 2022; 18:30-20:00 JST

Online (Zoom Webinar)


■Participation Fee:




Dr. Shigeki Yamada (Lecturer, Department of Neurosurgery, Graduate School of Medical Sciences, Nagoya City University)
Dr. Shigeki Yamada was born in the City of Nagoya. After graduating from the Gifu University Graduate School of Medicine in 1997, he joined the medical office of the Kyoto University Department of Neurosurgery. In 2001, he began the doctoral program at Kyoto University Graduate School of Medicine and Faculty of Medicine, studying genetic analysis, medical statistics, and epidemiology. He began a collaborative research initiative with the University of Tokyo Institute of Industrial Science in 2002. In 2004, he attended the Centre National de Génotypage (the National Center of Human Genomics Research) in France. He earned his Doctor of Medicine degree in 2004, was named a board-certified neurosurgeon of the Japan Neurosurgical Society in 2005, and was certified as a medical specialist in stroke by the Japan Stroke Society in 2007. From 2017 to the present, Professor Yamada has been involved in joint industry-academia initiatives spanning the fields of medicine and engineering in which he is researching 3D image analysis with Fujifilm Co., Ltd. and 3D gait analysis with Digital Standard Co., Ltd. From 2013 to 2019, Professor Yamada studied under Dr. Masatsune Ishikawa at the Rakuwakai Otowa Hospital and developed a specialty in idiopathic Normal Pressure Hydrocephalus (iNPH). He served at the Department of Neurosurgery at the Shiga University of Medical Science from 2019 to 2022. In October 2022, he assumed a role at the Nagoya City University Department of Neurosurgery where he will be involved in research to raise awareness of iNPH, develop new diagnostic and therapeutic methods for iNPH, and conduct research to elucidate its pathophysiology.

Back to Events